at CNBC.com (Nov 12, 2013)
Vanda Pharmaceuticals (VNDA +1%) moves up after Jefferies raises its price target from $6 to $7, saying that a Tasimelteon filing is forthcoming. The firm notes that VNDA has plenty of cash to make it through potential Tasi approval, and it continues to develop market awareness and build pre-launch demand critical mass.
From other sites
at CNBC.com (Mar 5, 2013)
at MarketWatch.com (Jan 27, 2011)
at MarketWatch.com (Nov 15, 2010)